A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry
oleh: Yanwen Chen, Travis B. Lear, John W. Evankovich, Mads B. Larsen, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Laura Salminen, Daniel P. Camarco, Karina C. Lockwood, Ferhan Tuncer, Jie Liu, Michael M. Myerburg, John F. McDyer, Yuan Liu, Toren Finkel, Bill B. Chen
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-06-01 |
Deskripsi
The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.